Literature DB >> 21962823

Dosimetric comparison of helical tomotherapy, RapidArc, and a novel IMRT & Arc technique for esophageal carcinoma.

Spencer Martin1, Jeff Z Chen, A Rashid Dar, Slav Yartsev.   

Abstract

PURPOSE: To compare radiotherapy treatment plans for mid- and distal-esophageal cancer with primary involvement of the gastroesophageal (GE) junction using a novel IMRT & Arc technique (IMRT & Arc), helical tomotherapy (HT), and RapidArc (RA1 and RA2). METHODS AND MATERIALS: Eight patients treated on HT for locally advanced esophageal cancer with radical intent were re-planned for RA and IMRT&Arc. RA plans employed single and double arcs (RA1 and RA2, respectively), while IMRT&Arc plans had four fixed-gantry IMRT fields and a conformal arc. Dose-volume histogram statistics, dose uniformity, and dose homogeneity were analyzed to compare treatment plans.
RESULTS: RA2 plans showed significant improvement over RA1 plans in terms of OAR dose and PTV dose uniformity and homogeneity. HT plan provided best dose uniformity (p=0.001) and dose homogeneity (p=0.002) to planning target volume (PTV), while IMRT&amp;Arc and RA2 plans gave lowest dose to lungs among four radiotherapy techniques with acceptable PTV dose coverage. Mean V(10) of the lungs was significantly reduced by the RA2 plans compared to IMRT&amp;Arc (40.3%, p=0.001) and HT (66.2%, p<0.001) techniques. Mean V(15) of the lungs for the RA2 plans also showed significant improvement over the IMRT&amp;Arc (25.2%, p=0.042) and HT (34.8%, p=0.027) techniques. These improvements came at the cost of higher doses to the heart volume compared to HT and IMRT&amp;Arc techniques. Mean lung dose (MLD) for the IMRT&amp;Arc technique (21.2 ± 5.0% of prescription dose) was significantly reduced compared to HT (26.3%, p=0.004), RA1 (23.3%, p=0.028), and RA2 (23.2%, p=0.017) techniques.
CONCLUSION: The IMRT&amp;Arc technique is a good option for treating esophageal cancer with thoracic involvement. It achieved optimal low dose to the lungs and heart with acceptable PTV coverage. HT is a good option for treating esophageal cancer with little thoracic involvement as it achieves superior dose conformality and uniformity. The RA2 technique provided for improved treatment plans using additional arcs with low doses to the lungs at the cost of increased heart dose. Plan quality could still be improved through the use of additional arcs.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21962823     DOI: 10.1016/j.radonc.2011.08.030

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  20 in total

1.  FusionArc optimization: a hybrid volumetric modulated arc therapy (VMAT) and intensity modulated radiation therapy (IMRT) planning strategy.

Authors:  Martha M Matuszak; Jennifer M Steers; Troy Long; Daniel L McShan; Benedick A Fraass; H Edwin Romeijn; Randall K Ten Haken
Journal:  Med Phys       Date:  2013-07       Impact factor: 4.071

2.  High FDG uptake areas on pre-radiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for locally advanced oesophageal cancer.

Authors:  Jérémie Calais; Bernard Dubray; Lamyaa Nkhali; Sebastien Thureau; Charles Lemarignier; Romain Modzelewski; Isabelle Gardin; Frederic Di Fiore; Pierre Michel; Pierre Vera
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-02-14       Impact factor: 9.236

3.  Is dose escalation achievable for esophageal carcinoma?

Authors:  Laure Vieillevigne; Marie Vidal; Françoise Izar; Michel Rives
Journal:  Rep Pract Oncol Radiother       Date:  2015-01-05

4.  Comparison of a Hybrid IMRT/VMAT technique with non-coplanar VMAT and non-coplanar IMRT for unresectable olfactory neuroblastoma using the RayStation treatment planning system-EUD, NTCP and planning study.

Authors:  Vijay P Raturi; Atsushi Motegi; Sadamoto Zenda; Naoki Nakamura; Hidehiro Hojo; Shin-Ichiro Kageyama; Masayuki Okumura; Toshiya Rachi; Hajime Ohyoshi; Hidenobu Tachibana; Kana Motegi; Takaki Ariji; Masaki Nakamura; Yasuhiro Hirano; Hidenari Hirata; Tetsuo Akimoto
Journal:  J Radiat Res       Date:  2021-05-12       Impact factor: 2.724

5.  Improved oncologic outcomes with image-guided intensity-modulated radiation therapy using helical tomotherapy in locally advanced hepatocellular carcinoma.

Authors:  Hong In Yoon; Ik Jae Lee; Kwang-Hyub Han; Jinsil Seong
Journal:  J Cancer Res Clin Oncol       Date:  2014-05-09       Impact factor: 4.553

6.  Predictive factors for acute radiation pneumonitis in postoperative intensity modulated radiation therapy and volumetric modulated arc therapy of esophageal cancer.

Authors:  Yaqin Zhao; Lu Chen; Shu Zhang; Qiang Wu; Xiaoqin Jiang; Hong Zhu; Jin Wang; Zhiping Li; Yong Xu; Ying Jie Zhang; Sen Bai; Feng Xu
Journal:  Thorac Cancer       Date:  2015-01-07       Impact factor: 3.500

7.  Reduced lung dose during radiotherapy for thoracic esophageal carcinoma: VMAT combined with active breathing control for moderate DIBH.

Authors:  Guanzhong Gong; Ruozheng Wang; Yujie Guo; Deyin Zhai; Tonghai Liu; Jie Lu; Jinhu Chen; Chengxin Liu; Yong Yin
Journal:  Radiat Oncol       Date:  2013-12-20       Impact factor: 3.481

Review 8.  Radiotherapy for tumors of the stomach and gastroesophageal junction--a review of its role in multimodal therapy.

Authors:  Daniel Buergy; Frank Lohr; Tobias Baack; Kerstin Siebenlist; Stefan Haneder; Henrik Michaely; Frederik Wenz; Judit Boda-Heggemann
Journal:  Radiat Oncol       Date:  2012-11-16       Impact factor: 3.481

9.  A broad scope knowledge based model for optimization of VMAT in esophageal cancer: validation and assessment of plan quality among different treatment centers.

Authors:  Antonella Fogliata; Giorgia Nicolini; Alessandro Clivio; Eugenio Vanetti; Sarbani Laksar; Angelo Tozzi; Marta Scorsetti; Luca Cozzi
Journal:  Radiat Oncol       Date:  2015-10-31       Impact factor: 3.481

10.  Analysis of Intensity-Modulated Radiation Therapy (IMRT), Proton and 3D Conformal Radiotherapy (3D-CRT) for Reducing Perioperative Cardiopulmonary Complications in Esophageal Cancer Patients.

Authors:  Ted C Ling; Jerry M Slater; Prashanth Nookala; Rachel Mifflin; Roger Grove; Anh M Ly; Baldev Patyal; Jerry D Slater; Gary Y Yang
Journal:  Cancers (Basel)       Date:  2014-12-05       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.